Symbols / ANRO $22.36 -7.95%
ANRO Chart
About
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 694.64M |
| Enterprise Value | 582.23M | Income | -62.26M | Sales | — |
| Book/sh | 4.11 | Cash/sh | 4.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | 76 | IPO | — |
| P/E | — | Forward P/E | -9.81 | PEG | — |
| P/S | — | P/B | 5.45 | P/C | — |
| EV/EBITDA | -8.87 | EV/Sales | — | Quick Ratio | 15.24 |
| Current Ratio | 15.42 | Debt/Eq | 22.77 | LT Debt/Eq | — |
| EPS (ttm) | -2.12 | EPS next Y | -2.28 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -24.48% |
| ROE | -45.01% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 31.07M |
| Shs Float | 18.27M | Short Float | 8.07% | Short Ratio | 9.35 |
| Short Interest | — | 52W High | 25.17 | 52W Low | 1.60 |
| Beta | 2.59 | Avg Volume | 257.70K | Volume | 362.60K |
| Target Price | $33.62 | Recom | Strong_buy | Prev Close | $24.29 |
| Price | $22.36 | Change | -7.95% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$33.63
Mean price target
2. Current target
$22.36
Latest analyst target
3. DCF / Fair value
$-21.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$22.36
Low
$22.00
High
$50.00
Mean
$33.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | main | Chardan Capital | Buy → Buy | $30 |
| 2026-03-17 | main | Wedbush | Neutral → Neutral | $22 |
| 2026-02-17 | main | BTIG | Buy → Buy | $28 |
| 2026-01-05 | main | Chardan Capital | Buy → Buy | $30 |
| 2025-11-17 | init | BTIG | — → Buy | $27 |
| 2025-11-13 | main | Baird | Outperform → Outperform | $22 |
| 2025-11-12 | main | Jefferies | Buy → Buy | $25 |
| 2025-10-24 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-10-20 | main | Baird | Outperform → Outperform | $16 |
| 2025-09-29 | init | Chardan Capital | — → Buy | $15 |
| 2025-08-18 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-05-15 | reit | Wedbush | Neutral → Neutral | $4 |
| 2025-04-07 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2024-12-16 | init | Jones Trading | — → Buy | $18 |
| 2024-11-13 | main | Stifel | Buy → Buy | $10 |
| 2024-10-23 | down | Wedbush | Outperform → Neutral | $4 |
| 2024-10-23 | main | Baird | Outperform → Outperform | $10 |
| 2024-09-10 | reit | Wedbush | Outperform → Outperform | $29 |
| 2024-09-03 | init | Wedbush | — → Outperform | $29 |
- Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6% - Time to Sell? - MarketBeat ue, 17 Mar 2026 17
- Investors commit $120M to Alto’s treatment‑resistant depression drug - Stock Titan Mon, 16 Mar 2026 11
- Alto Neuroscience Stock Pre-Market (-7.0%): Geopolitical Tensions Spark Risk-Off Move - Trefis ue, 10 Mar 2026 10
- Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile - TipRanks ue, 17 Mar 2026 21
- Alto Neuroscience (ANRO) Reports FY25 Loss of $2.19/Share - AlphaStreet Mon, 16 Mar 2026 14
- Alto bets on 0.87-effect depression combo as cash runway to 2028 - Stock Titan Mon, 16 Mar 2026 10
- Jefferies Maintains Buy on ANRO, PT Raised to $35 on Mar 16, 2026 - Meyka ue, 17 Mar 2026 01
- Chardan Capital Reiterates "Buy" Rating for Alto Neuroscience (NYSE:ANRO) - MarketBeat ue, 17 Mar 2026 13
- Jefferies raises Alto Neuroscience stock price target on pipeline - Investing.com Mon, 16 Mar 2026 16
- Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy - Yahoo Finance hu, 23 Oct 2025 07
- Alto Neuroscience (NYSE:ANRO) Price Target Raised to $22.00 - MarketBeat ue, 17 Mar 2026 13
- Alto Neuroscience Secures $120 Million Private Placement Financing - TipRanks Mon, 16 Mar 2026 11
- Alto Neuroscience (NYSE: ANRO) secures $120M PIPE to fund ALTO-207 - Stock Titan Mon, 16 Mar 2026 11
- Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company - Yahoo Finance Fri, 26 Dec 2025 08
- Neuropsychiatric biotech Alto joins Stifel 2026 virtual CNS forum - Stock Titan Fri, 13 Mar 2026 12
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15000 | 190833 | — | Purchase at price 12.53 - 13.22 per share. | SAVITZ ADAM | Officer | — | 2024-07-10 00:00:00 | I |
| 1 | 6150 | 100628 | — | Purchase at price 15.80 - 16.56 per share. | SMITH NICHOLAS CONRAD | Chief Financial Officer | — | 2024-03-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -59.55M | -34.56M | -27.00M | -8.83M |
| TotalUnusualItems | 525.00K | -369.00K | -107.00K | |
| TotalUnusualItemsExcludingGoodwill | 525.00K | -369.00K | -107.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -61.43M | -36.30M | -27.71M | -9.19M |
| ReconciledDepreciation | 502.00K | 373.00K | 342.00K | 145.00K |
| EBITDA | -59.55M | -34.56M | -27.37M | -8.94M |
| EBIT | -60.06M | -34.94M | -27.71M | -9.08M |
| NetInterestIncome | 7.48M | 979.00K | 114.00K | 2.00K |
| InterestExpense | 1.38M | 1.37M | 0.00 | |
| InterestIncome | 8.85M | 2.35M | 114.00K | 2.00K |
| NormalizedIncome | -61.43M | -36.30M | -27.34M | -9.08M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -61.43M | -36.30M | -27.71M | -9.19M |
| TotalExpenses | 68.61M | 37.81M | 27.45M | 9.29M |
| TotalOperatingIncomeAsReported | -68.61M | -37.81M | -29.19M | -12.06M |
| DilutedAverageShares | 24.60M | 25.57M | 12.98M | 9.73M |
| BasicAverageShares | 24.60M | 25.57M | 12.98M | 9.73M |
| DilutedEPS | -2.50 | -1.42 | -2.13 | -0.94 |
| BasicEPS | -2.50 | -1.42 | -2.13 | -0.94 |
| DilutedNIAvailtoComStockholders | -61.43M | -36.30M | -27.71M | -9.19M |
| NetIncomeCommonStockholders | -61.43M | -36.30M | -27.71M | -9.19M |
| NetIncome | -61.43M | -36.30M | -27.71M | -9.19M |
| NetIncomeIncludingNoncontrollingInterests | -61.43M | -36.30M | -27.71M | -9.19M |
| NetIncomeContinuousOperations | -61.43M | -36.30M | -27.71M | -9.19M |
| PretaxIncome | -61.43M | -36.30M | -27.71M | -9.19M |
| OtherIncomeExpense | -297.00K | 525.00K | -369.00K | -107.00K |
| OtherNonOperatingIncomeExpenses | -297.00K | 525.00K | ||
| GainOnSaleOfSecurity | 525.00K | -369.00K | -107.00K | |
| NetNonOperatingInterestIncomeExpense | 7.48M | 979.00K | 114.00K | 2.00K |
| InterestExpenseNonOperating | 1.38M | 1.37M | 0.00 | |
| InterestIncomeNonOperating | 8.85M | 2.35M | 114.00K | 2.00K |
| OperatingIncome | -68.61M | -37.81M | -27.45M | -9.08M |
| OperatingExpense | 68.61M | 37.81M | 27.45M | 9.29M |
| OtherOperatingExpenses | -1.74M | -2.97M | ||
| ResearchAndDevelopment | 47.00M | 30.29M | 23.69M | 8.37M |
| SellingGeneralAndAdministration | 21.61M | 7.52M | 5.50M | 3.90M |
| GeneralAndAdministrativeExpense | 21.61M | 7.52M | 5.50M | 3.90M |
| OtherGandA | 21.61M | 7.52M | 5.50M | 3.90M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 210.00K |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 210.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 26.99M | 25.57M | 25.57M | 25.57M |
| ShareIssued | 26.99M | 25.57M | 25.57M | 25.57M |
| TotalDebt | 16.94M | 9.99M | 9.75M | 0.00 |
| TangibleBookValue | 151.46M | -71.67M | -38.41M | -12.48M |
| InvestedCapital | 163.02M | -61.81M | -28.94M | -12.48M |
| WorkingCapital | 159.33M | 79.78M | 43.66M | 25.87M |
| NetTangibleAssets | 151.46M | -71.67M | -38.41M | -12.48M |
| CapitalLeaseObligations | 5.39M | 125.00K | 283.00K | 0.00 |
| CommonStockEquity | 151.46M | -71.67M | -38.41M | -12.48M |
| TotalCapitalization | 163.02M | -61.81M | -28.94M | -12.48M |
| TotalEquityGrossMinorityInterest | 151.46M | -71.67M | -38.41M | -12.48M |
| StockholdersEquity | 151.46M | -71.67M | -38.41M | -12.48M |
| GainsLossesNotAffectingRetainedEarnings | -101.00K | -79.00K | -46.00K | -22.00K |
| OtherEquityAdjustments | -101.00K | -79.00K | -46.00K | -22.00K |
| RetainedEarnings | -138.40M | -76.97M | -40.66M | -12.95M |
| AdditionalPaidInCapital | 289.95M | 5.37M | 2.30M | 494.00K |
| CapitalStock | 3.00K | 0.00 | 0.00 | 0.00 |
| CommonStock | 3.00K | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 26.08M | 158.30M | 89.26M | 41.27M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 16.07M | 152.69M | 83.70M | 39.46M |
| OtherNonCurrentLiabilities | 123.00K | |||
| PreferredSecuritiesOutsideStockEquity | 0.00 | 141.48M | 72.23M | 38.16M |
| DerivativeProductLiabilities | 0.00 | 1.35M | 1.88M | 1.30M |
| LongTermDebtAndCapitalLeaseObligation | 16.07M | 9.86M | 9.46M | |
| LongTermCapitalLeaseObligation | 4.52M | 0.00 | ||
| LongTermDebt | 11.56M | 9.86M | 9.46M | |
| CurrentLiabilities | 10.01M | 5.61M | 5.56M | 1.81M |
| OtherCurrentLiabilities | 515.00K | 193.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 870.00K | 125.00K | 283.00K | |
| CurrentCapitalLeaseObligation | 870.00K | 125.00K | 283.00K | 0.00 |
| PayablesAndAccruedExpenses | 9.14M | 5.49M | 5.28M | 1.81M |
| CurrentAccruedExpenses | 7.56M | 4.41M | 3.67M | 1.21M |
| InterestPayable | 78.00K | 84.00K | 0.00 | |
| Payables | 1.58M | 1.07M | 1.61M | 600.00K |
| AccountsPayable | 1.58M | 1.07M | 1.61M | 600.00K |
| TotalAssets | 177.54M | 86.63M | 50.85M | 28.79M |
| TotalNonCurrentAssets | 8.21M | 1.24M | 1.63M | 1.11M |
| OtherNonCurrentAssets | 504.00K | 131.00K | 461.00K | 50.00K |
| NetPPE | 7.70M | 1.11M | 1.17M | 1.06M |
| AccumulatedDepreciation | -1.00M | -684.00K | -579.00K | -244.00K |
| GrossPPE | 8.71M | 1.79M | 1.75M | 1.30M |
| Leases | 246.00K | 0.00 | ||
| OtherProperties | 7.34M | 1.20M | 1.13M | 818.00K |
| MachineryFurnitureEquipment | 1.12M | 589.00K | 620.00K | 486.00K |
| BuildingsAndImprovements | 5.04M | 0.00 | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 169.34M | 85.39M | 49.22M | 27.68M |
| OtherCurrentAssets | 30.00K | 112.00K | 213.00K | |
| CurrentDeferredAssets | 0.00 | 2.21M | 0.00 | |
| PrepaidAssets | 1.08M | 522.00K | 330.00K | 236.00K |
| Receivables | 8.00K | 333.00K | 1.74M | |
| OtherReceivables | 8.00K | 333.00K | 248.00K | |
| AccountsReceivable | 333.00K | 1.50M | ||
| CashCashEquivalentsAndShortTermInvestments | 168.23M | 82.55M | 48.34M | 25.70M |
| CashAndCashEquivalents | 168.23M | 82.55M | 48.34M | 25.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -49.50M | -33.92M | -21.13M | -9.94M |
| IssuanceOfDebt | 0.00 | 9.82M | 0.00 | |
| IssuanceOfCapitalStock | 137.58M | 70.00M | 34.30M | 31.89M |
| CapitalExpenditure | -2.08M | -470.00K | -732.00K | -680.00K |
| InterestPaidSupplementalData | 999.00K | 912.00K | 0.00 | |
| EndCashPosition | 168.73M | 82.55M | 48.34M | 25.70M |
| BeginningCashPosition | 82.55M | 48.34M | 25.70M | 4.01M |
| EffectOfExchangeRateChanges | -11.00K | -8.00K | -24.00K | -50.00K |
| ChangesInCash | 86.19M | 34.21M | 22.66M | 21.75M |
| FinancingCashFlow | 135.69M | 68.13M | 43.79M | 31.69M |
| CashFlowFromContinuingFinancingActivities | 135.69M | 68.13M | 43.79M | 31.69M |
| NetOtherFinancingCharges | -2.08M | -2.05M | -341.00K | -205.00K |
| ProceedsFromStockOptionExercised | 187.00K | 181.00K | ||
| NetPreferredStockIssuance | 0.00 | 70.00M | 34.26M | 31.89M |
| PreferredStockIssuance | 0.00 | 70.00M | 34.26M | 31.89M |
| NetCommonStockIssuance | 137.58M | 0.00 | 43.00K | 7.00K |
| CommonStockIssuance | 137.58M | 0.00 | 43.00K | 7.00K |
| NetIssuancePaymentsOfDebt | 0.00 | 9.82M | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | 9.82M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 9.82M | 0.00 | |
| InvestingCashFlow | -2.08M | -470.00K | -732.00K | -680.00K |
| CashFlowFromContinuingInvestingActivities | -2.08M | -470.00K | -732.00K | -680.00K |
| CapitalExpenditureReported | -2.08M | -470.00K | -732.00K | -680.00K |
| OperatingCashFlow | -47.42M | -33.45M | -20.39M | -9.26M |
| CashFlowFromContinuingOperatingActivities | -47.42M | -33.45M | -20.39M | -9.26M |
| ChangeInWorkingCapital | 4.06M | -698.00K | 4.58M | -572.00K |
| ChangeInPayablesAndAccruedExpense | 4.52M | -989.00K | 3.48M | 1.10M |
| ChangeInAccruedExpense | 4.01M | -357.00K | 2.47M | 639.00K |
| ChangeInPayable | 516.00K | -632.00K | 1.01M | 458.00K |
| ChangeInAccountPayable | 516.00K | -632.00K | 1.01M | 458.00K |
| ChangeInPrepaidAssets | -463.00K | 291.00K | -59.00K | -384.00K |
| ChangeInReceivables | 325.00K | 1.16M | -1.28M | |
| ChangesInAccountReceivables | 325.00K | 1.16M | -1.28M | |
| OtherNonCashItems | 1.76M | 151.00K | 263.00K | 18.00K |
| StockBasedCompensation | 7.63M | 2.89M | 1.76M | 227.00K |
| DepreciationAmortizationDepletion | 502.00K | 373.00K | 342.00K | 145.00K |
| DepreciationAndAmortization | 502.00K | 373.00K | 342.00K | 145.00K |
| OperatingGainsLosses | 52.00K | 140.00K | 369.00K | 107.00K |
| GainLossOnInvestmentSecurities | -525.00K | 369.00K | 107.00K | |
| NetIncomeFromContinuingOperations | -61.43M | -36.30M | -27.71M | -9.19M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ANRO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|